This is the Firebrick Pharma (FRE) authorised company representative account on HotCopper. My name is Peter Molloy (‘Dr M’ to those who may know me on this forum) and I am the Executive Chairman of FRE. I will be responsible for the posts under this account.
The purpose of this account will be to post news relevant to FRE, help clarify announcements where needed, and respond to investor enquiries, in compliance with ASX’s disclosure guidelines and requirements.
More specifically, the purposes of the account will be:
- To comment on FRE ASX announcements. In general, ASX announcements can be limited in scope, but because the business of FRE can involve complex scientific matters, e.g., clinical trials and regulatory processes, some elaboration may be warranted and useful to investors, within ASX disclosure rules.
- To respond to questions that are posted on the site. These questions must be related to the business of Firebrick Pharma and they must be asked in a respectful and informed manner. We will not necessarily respond to all questions, and will not respond to any questions that seek information that has not been publicly disclosed already, including proprietary and confidential information.
- To clarify and correct any misinformation or incorrect statements posted about FRE on this or other platforms.
- To share public domain information: All information posted under this account will already be in the public domain through FRE announcements, published articles or other publicly-available sources. One purpose of this account will be to synthesise and report on that information in a way that is helpful, especially for new investors.
I hope you find this account useful.We also provide an e-newsletter to shareholders who share their email addresses with us. You can subscribe to that newsletter on our website homepage or by email to < investors [at] firebrickpharma.com >.
Peter Molloy
Executive Chairman
Firebrick Pharma Ltd
Add to My Watchlist
What is My Watchlist?
